ArticleScientific reports2025
Explainable ensemble learning for Epstein-Barr virus risk prediction in ulcerative colitis and Crohn's disease using routine biomarkers.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Epstein-Barr virus (EBV) exacerbates inflammatory bowel disease (IBD) and is challenging to monitor with invasive or costly tests. We investigated whether explainable machine learning can predict EBV infection from routine clinical data in ulcerative colitis (UC) and Crohn's disease (CD). In this retrospective study (June 2018-December 2022), EBV status was defined by EBV-DNA > 400 copies/mL. After cleaning, the training cohort (2018-2019) included 174 patients (CD = 122, UC = 52) and the test cohort (2020-2022) included 100 patients. Twenty-one demographic, clinical, and laboratory variables were modeled with ten classifiers; the four best were stacked. Five-fold cross-validation and resampling addressed overfitting and class imbalance. Shapley Additive Explanations (SHAP) provided model interpretability. The ensemble model exhibited high predictive accuracy, achieving area under the ROC curve (AUC) values of 0.93 (overall), 0.97 (CD), and 0.88 (UC) in the training set. In the validation set, AUC values were 0.95 (overall), 0.89 (CD), and 0.97 (UC). SHAP analysis identified age, hemoglobin (HB), total bile acids (TBA), and platelet count (PLT) as significant predictors. Age increased predicted risk in the overall and CD cohorts but decreased risk in UC. TBA emerged as a critical predictor in UC, reflecting its role in bile acid metabolism, while PLT influenced risk across the total patient population, indicating its involvement in coagulation and immune responses. An explainable stacking model using routine biomarkers accurately predicts EBV infection in IBD and reveals subtype-specific determinants. Prospective, multi-center and time-aware validation, and integration into decision-support tools are warranted for clinical deployment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.